我国原创丁肝新药获批上市

Core Viewpoint - The approval of the monoclonal antibody, Libeveita (brand name "Huayounuo"), for the treatment of chronic hepatitis D virus infection marks a significant achievement in the field of viral hepatitis, being the first monoclonal antibody approved globally for this purpose [1]. Group 1: Drug Development and Approval - Libeveita is a fully independent innovation completed by a Chinese team, from scientific discovery to drug development, which is rare globally [1]. - The drug has received approval from the National Medical Products Administration of China [1]. Group 2: Mechanism of Action - Libeveita works by specifically binding to the preS1 protein region of the hepatitis B/D virus, blocking the virus from binding to its receptor NTCP, thereby preventing infection or reinfection of liver cells [1]. Group 3: Impact on Public Health - The introduction of Libeveita is expected to provide a more economical, effective, and accessible treatment option for global patients, contributing to the goal of eliminating the public health threat of viral hepatitis by 2030 [1].